Plus Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Plus Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Plus Therapeutics Inc Strategy Report
- Understand Plus Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Plus Therapeutics Inc (Plus Therapeutics), formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.
Headquarters
United States of America
Address
4200 Marathon Blvd Ste 200, Austin, Texas, 78756-3433
Website
www.plustherapeutics.com
Telephone
1 858 4580900
No of Employees
20
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PSTV (NASD)
Revenue (2022)
$4.9M
2093.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
34.3%
(2022 vs 2021)
Market Cap*
$7.2M
Net Profit Margin (2022)
XYZ
97.0%
(2022 vs 2021)
* As of and is in US$
Plus Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Doceplus- Relapsed Small Cell Lung Cancer |
| RNL- Recurrent Glioblastoma, Ovarian Carcinomatosis, Leptomeningeal Carcinomatosis, Breast Cancer, and Cancers of Head, Neck and Liver |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with K2bio for the creation of novel diagnostics for tumor cell and molecular biomarker studies in cerebrospinal fluid (csf). |
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Biocept to exclusively license Biocept's CNSide, a CSF-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy. |
| 2023 | Contracts/Agreements | In May, the company and Piramal Pharma Solutions expanded their partnership to produce additional cGMP liposome intermediate drug products. |
Competitor Comparison
| Key Parameters | Plus Therapeutics Inc | Bayer AG | VBI Vaccines Inc | MediciNova Inc | Notable Labs Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | United States of America | United States of America | United States of America |
| City | Austin | Leverkusen | Cambridge | La Jolla | Foster City |
| State/Province | Texas | Nordrhein-Westfalen | Massachusetts | California | California |
| No. of Employees | 20 | 99,723 | 190 | 13 | 7 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard J. Hawkins | Chairman | Executive Board | 2018 | 75 |
| Marc H. Hedrick, M.D. | Director; President; Chief Executive Officer | Executive Board | 2014 | 60 |
| Andrew Sims | Vice President; Chief Financial Officer | Senior Management | 2020 | 50 |
| Norman LaFrance | Senior Vice President; Chief Medical Officer | Senior Management | 2021 | 75 |
| Melissa Moore | Senior Vice President - Clinical Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward